Titlebook: Managing BRCA Mutation Carriers; Anees B. Chagpar Book 2017 Springer International Publishing AG 2017 Pathology of BCRA.DNA damage repair.

鸟场

书目名称Managing BRCA Mutation Carriers影响因子(影响力)




书目名称Managing BRCA Mutation Carriers影响因子(影响力)学科排名




书目名称Managing BRCA Mutation Carriers网络公开度




书目名称Managing BRCA Mutation Carriers网络公开度学科排名




书目名称Managing BRCA Mutation Carriers被引频次




书目名称Managing BRCA Mutation Carriers被引频次学科排名




书目名称Managing BRCA Mutation Carriers年度引用




书目名称Managing BRCA Mutation Carriers年度引用学科排名




书目名称Managing BRCA Mutation Carriers读者反馈




书目名称Managing BRCA Mutation Carriers读者反馈学科排名

galley

s.Written by experts in their fields.Includes supplementary As there are a number of nuances in terms of how to manage mutation carriers (both with and without a concomitant diagnosis of breast cancer), this text provides a comprehensive, state-of-the art review of this field. It represents a valuab

Forsake

Risk Assessment for Breast Cancer,ic testing; and most important, ensure that the patient follows through. With each of these steps, a certain proportion of patients is lost. Mary-Claire King, the human geneticist who discovered the . mutation, once stated that “to identify a woman as a carrier only after she develops cancer is a failure of cancer prevention.” We can do better.

aneurysm

mortgage

制定法律

FLEET

Risk Assessment for Breast Cancer,fected . mutation carriers before they develop breast cancer can reduce their risk and increase survival through increased intensity and frequency of screening, prophylactic surgery, and use of chemopreventive agents. Although the tools for genetic testing have been available for the past 20 years,

Indolent

Genetic Evaluation for Women at Increased Risk,family history of cancer that may be associated with a hereditary cancer predisposition. The collection of an accurate, cancer-focused family history is the foundation of this risk assessment. Professional organizations have created guidelines outlining when patients should be referred to a provider

吹牛大王

Imaging Screening and Surveillance,sitivity of screening MRI in this population is 90–95%, more than twice that of mammography, with a specificity of over 90% after the first round of screening. Ten-year breast cancer-free survival, though likely somewhat lower than that with risk-reducing mastectomy, is at least 90%. The incremental

sigmoid-colon

Risk-Reducing Surgery for , Genetic Mutation Carriers,y has been shown to reduce the risk of breast cancer by 90% or more among high-risk women including . mutation carriers. The decision to undergo prophylactic surgery is a choice that patients make, in conjunction with their multidisciplinary healthcare team which often includes genetic counselors, s